Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick R Appelbaum

Showing results (201-210 of 339) with videos related to

Pageof 34
Sort By:
Leukemia & Lymphoma|October 23, 2002
Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantationUwe Platzbecker, Ted Gooley, Claudio Anasetti, et al.
Blood|April 4, 2002
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host diseasePaul A Carpenter, Frederick R Appelbaum, Lawrence Corey, et al.
The New England Journal of Medicine|November 26, 2010
Reduced mortality after allogeneic hematopoietic-cell transplantationTed A Gooley, Jason W Chien, Steven A Pergam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2007
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997Ian W Flinn, Donna S Neuberg, Michael R Grever, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 6, 2010
Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantationMarcello Rotta, Barry E Storer, Rainer Storb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studiesJennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
Blood|July 2, 2002
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trialMary E D Flowers, Pablo M Parker, Laura J Johnston, et al.
Blood|July 13, 2013
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remissionRoland B Walter, Sarah A Buckley, John M Pagel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantationPaul J Martin, George W Counts, Frederick R Appelbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapyMegan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Pageof 34

Showing results (201-210 of 339) with videos related to

Sort By:
Pageof 34
Leukemia & Lymphoma|October 23, 2002
Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantationUwe Platzbecker, Ted Gooley, Claudio Anasetti, et al.
Blood|April 4, 2002
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host diseasePaul A Carpenter, Frederick R Appelbaum, Lawrence Corey, et al.
The New England Journal of Medicine|November 26, 2010
Reduced mortality after allogeneic hematopoietic-cell transplantationTed A Gooley, Jason W Chien, Steven A Pergam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2007
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997Ian W Flinn, Donna S Neuberg, Michael R Grever, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 6, 2010
Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantationMarcello Rotta, Barry E Storer, Rainer Storb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studiesJennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
Blood|July 2, 2002
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trialMary E D Flowers, Pablo M Parker, Laura J Johnston, et al.
Blood|July 13, 2013
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remissionRoland B Walter, Sarah A Buckley, John M Pagel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantationPaul J Martin, George W Counts, Frederick R Appelbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapyMegan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Pageof 34